When science and biology combine – the outlook for ADCs in cancer drug developmentAntibody Drug Conjugates (ADCs) are treatments formed by the conjugation of monoclonal antibodies and cytotoxic agents. Although just Share XWhen science and biology combine – the outlook for ADCs in cancer drug developmenthttps://pharmaphorum.com/partner-content-oncology/science-biology-combine-outlook-adcs-cancer-drug-development/
Oncology – the current landscape and what it means for the futureThe WHO reports that in 2015, cancer was the second highest cause of death globally – responsible for Share XOncology – the current landscape and what it means for the futurehttps://pharmaphorum.com/partner-content-oncology/oncology-current-landscape-means-future/
What oncologists need from you when launching a new therapyAt the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is Share XWhat oncologists need from you when launching a new therapyhttps://pharmaphorum.com/partner-content/oncologists-need-launching-new-therapy/
Critical factors for successful early phase oncology trials – an analysisEarly phase trials have always been critical within pharmaceutical development, establishing the safety and potential efficacy of a Share XCritical factors for successful early phase oncology trials – an analysishttps://pharmaphorum.com/cancer/critical-factors-successful-early-phase-oncology-trials-analysis/
